National Announces Expansion of Equity Research Team
September 27 2018 - 7:30AM
National Holdings Corporation (NASDAQ: NHLD) (“National” or the
“Company”), a leading full-service independent brokerage,
investment banking, trading, insurance, accounting and asset
management firm, today announced the expansion of its equity
research team to include the following new hires:
- David Toti has joined as Managing Director of Equity
Research
- Matthew Galinko has joined as a Senior Equity Research Analyst,
Technology
- Paul Bienstock has joined as a Senior Equity Research Analyst,
Medical Devices
Michael Mullen, Chairman and Chief Executive Officer of National
stated, “We are extremely pleased to announce the expansion of our
equity research team which enables us to increase the quality and
depth of our research coverage. We believe these additions
underscore our commitment to providing our clients with high
quality investment ideas.”
Mr. Mullen added, “We welcome David, Matthew and Paul to our
growing team and look forward to the value they will add to our
research department.”
About David Toti David Toti has joined National
as Managing Director of Equity Research covering REITs. Prior to
joining National, Mr. Toti spent a combined fourteen years as a
Director or an Equity Research Analyst at a number of financial
institutions including Lehman Brothers, Citigroup, and BB&T
Capital Markets. During that time he has covered most real
estate sub-sectors and garnered several awards, including
Starmine’s “Top Stock Picker Award – 2015” for the REIT sector.
David holds a Bachelor of Architecture from Syracuse University and
an M.B.A. in Real Estate from the University of Wisconsin-Madison.
About Matthew Galinko Matthew Galinko has joined
National as a Senior Equity Research Analyst covering Technology
and focused on the Internet of Things. Mr. Galinko has covered the
technology sector since 2007, including small caps at Sidoti &
Company and multi-cap software at Battle Road Research. Mr. Galinko
holds a Bachelor of Arts degree in Economics with a minor in
Business from Brandeis University. About Paul
Bienstock Paul Bienstock has joined National as a Senior
Equity Research Analyst covering Medical Devices. Mr. Bienstock is
a seasoned professional who has spent nearly 20 years as an Analyst
at a number of institutions, with a strong focus on healthcare and
the medical device space. Mr. Bienstock has also covered the
investment grade/high yield credit space and most recently acted as
a Portfolio Manager focused on healthcare investments. Mr.
Bienstock holds a Bachelor of Arts degree from Brandeis University,
as well as a Master of Business Administration (MBA) degree from
New York University, a Master’s degree in Taxation from Pace
University, and is also a Certified Financial Advisor (CFA).
About National Holdings Corporation
National Holdings Corporation (NASDAQ: NHLD) is a full-service
investment banking and asset management firm that, through its
affiliates, provides a range of services, including independent
retail brokerage and advisory services, investment banking,
institutional sales and trading, equity research, financial
planning, market making, tax preparation and insurance, to
corporations, institutions, high net-worth and retail investors.
With over 1,000 advisors, registered reps, traders, sales
associates and corporate staff, National Holdings operates through
various subsidiaries including National Securities Corporation,
National Asset Management, Inc., National Insurance Corporation,
Gilman Ciocia, Inc. and GC Capital Corporation. Formed as a holding
company in 1999, National Holdings’ largest subsidiary National
Securities Corporation has been in business since 1947. National
Holdings is headquartered in New York and Florida. For more
information, visit www.nhld.com. Fortress Biotech,
Inc. (NASDAQ: FBIO) through its affiliate FBIO Acquisition, Inc.,
is a majority shareholder of NHLD.
FORWARD-LOOKING STATEMENTSThis press release
may contain certain forward-looking statements. Any such
statements, other than statements of historical fact, are based on
management’s current expectations, estimates, projections, beliefs
and assumptions about National Holdings, Inc., its current and
prospective portfolio investments, and its industry. These
statements are not guarantees of future performance and are subject
to risks, uncertainties and other factors, some of which are beyond
National Holdings, Inc.’s control, difficult to predict and could
cause actual results to differ materially from those expected or
forecasted in such forward-looking statements. Actual developments
and results are likely to vary materially from these estimates and
projections as a result of a number of factors, including those
described from time to time in National Holdings, Inc.’s filings
with the Securities and Exchange Commission. Such statements speak
only as of the time when made, and National undertakes no
obligation to update any such forward-looking statements, whether
as a result of new information, future events, or otherwise, except
as required by law.
CONTACTS:
MEDIA CONTACTEric Hazard for
National917-765-8720national@fullyvested.com
INVESTOR RELATIONSEmail:
ir@nhldcorp.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024